Newcastle University

About: Newcastle University is a education organization based out in Newcastle upon Tyne, United Kingdom. It is known for research contribution in the topics: Population & Context (language use). The organization has 31772 authors who have published 71187 publications receiving 2539147 citations. The organization is also known as: University of Newcastle upon Tyne.

Quantifying the error in estimated transfer functions with application to model order selection

Abstract: Previous results on estimating errors or error bounds on identified transfer functions have relied on prior assumptions about the noise and the unmodeled dynamics. This prior information took the form of parameterized bounding functions or parameterized probability density functions, in the time or frequency domain with known parameters. It is shown that the parameters that quantify this prior information can themselves be estimated from the data using a maximum likelihood technique. This significantly reduces the prior information required to estimate transfer function error bounds. The authors illustrate the usefulness of the method with a number of simulation examples. How the obtained error bounds can be used for intelligent model-order selection that takes into account both measurement noise and under-modeling is shown. Another simulation study compares the method to Akaike's well-known FPE and AIC criteria. >

The contribution of H LA to rheumatoid arthritis

Abstract: The contribution of genes within the major histocompatibility complex to rheumatoid arthritis has been calculated (Rotter & Landaw 1984). Separate data from hospital- and population-based studies of monozygotic twin concordance rates and sibling recurrence risks have been used, along with material from published haplotype-sharing studies. Using either source of information gives the same result, a contribution of 37%.

Chronic Myelogenous Leukemia

Abstract: The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly. Imatinib mesylate (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed. As relapses using single agent imatinib have occurred, particularly in advanced phase patients, the issue of whether combinations of other antileukemic agents with imatinib may yield improved results is addressed. In addition, data on new agents that have potential in the treatment of CML are reviewed. These agents are presented in the context of their molecular mechanism of action. The most recent data for stem cell transplantation, along with advances in nonmyeloablative transplants, are also reviewed. In Section I, Drs. Stephen O'Brien and Brian Druker update the current status of clinical trials with imatinib and review ongoing investigations into mechanisms of resistance and combinations of imatinib with other agents. They also present their views on integration of imatinib with other therapies. In Section II, Dr. Jorge Cortes describes the most recent data on novel therapies for CML, including farnesyl transferase inhibitors, arsenic trioxide, decitabine, and troxatyl, among others. These agents are discussed in the context of their molecular mechanism of action and rationale for use. In Section III, Dr. Jerald Radich updates the results of stem cell transplants for CML, including emerging data on nonmyeloablative transplants. He also presents data on using microarrays to stratify patients into molecularly defined risk groups.